This document discusses tubular and interstitial diseases, focusing on acute kidney injury (AKI) and acute tubular necrosis (ATN). It provides details on:
1) The pathogenesis of AKI involving tubular cell injury from ischemia or toxins, disturbances in blood flow causing vasoconstriction, and the repair process through growth factors and cytokines.
2) The morphology of ischemic AKI, seen as focal tubular necrosis and casts, and the morphology of toxic AKI varying by toxin but often involving necrosis.
3) The clinical course of AKI proceeding through initiation, maintenance, and recovery phases and sometimes being nonoliguric. Prognosis depends on the cause,
This PPT contains only a brief summery about ATN.
for more information about the topic please refer to the book and site found the ppt, or you can get In touch with me .
This PPT contains only a brief summery about ATN.
for more information about the topic please refer to the book and site found the ppt, or you can get In touch with me .
Acute Tubular Necrosis | DR RAI M. AMMAR | ALL MEDICAL DATA
by DR RAI M. AMMAR
www.facebook.com/drraiammar
www.twitter.com/drraiammar
www.instagram.com/drraiammar
www.linkedin.com/in/drraiammar
www.medicall.com.pk/blog/auther/drraiammar/
For Any Book or Notes Visit Our Website:
www.allmedicaldata.wordpress.com
www.drraiammar.blogspot.com
YOUTUBE CHANNEL :
https://www.youtube.com/channel/UCu-oR9V3OdFNTJW5yqXWXxA
ANY QUESTION ??
Get in touch with us at Any of the Above Social Media or Email at
drraiammar@gmail.com
allmedicaldata@gmail.com
Acute kidney injury (AKI) is a potentially life-threatening
syndrome that occurs primarily in hospitalized patients
and frequently complicates the course of critically ill
patient.
Acute Kidney Injury is is (abrupt) reduction in kidney functions as evidence by changed in laboratory values; serum creatinine, blood urea nitrogen(BUN)and urine output
Acute Tubular Necrosis | DR RAI M. AMMAR | ALL MEDICAL DATA
by DR RAI M. AMMAR
www.facebook.com/drraiammar
www.twitter.com/drraiammar
www.instagram.com/drraiammar
www.linkedin.com/in/drraiammar
www.medicall.com.pk/blog/auther/drraiammar/
For Any Book or Notes Visit Our Website:
www.allmedicaldata.wordpress.com
www.drraiammar.blogspot.com
YOUTUBE CHANNEL :
https://www.youtube.com/channel/UCu-oR9V3OdFNTJW5yqXWXxA
ANY QUESTION ??
Get in touch with us at Any of the Above Social Media or Email at
drraiammar@gmail.com
allmedicaldata@gmail.com
Acute kidney injury (AKI) is a potentially life-threatening
syndrome that occurs primarily in hospitalized patients
and frequently complicates the course of critically ill
patient.
Acute Kidney Injury is is (abrupt) reduction in kidney functions as evidence by changed in laboratory values; serum creatinine, blood urea nitrogen(BUN)and urine output
Acute kidney failure occurs when your kidneys suddenly become unable to filter waste products from your blood. When your kidneys lose their filtering ability, dangerous levels of wastes may accumulate, and your blood's chemical makeup may get out of balance
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Acute tubular necrosis
1. Tubular and Interstitial Diseases
• (1) ischemic or toxic tubular injury, leading to
acute kidney injury (AKI) or ATN and acute
renal failure, and
• (2) inflammatory reactions of the tubules and
interstitium (tubulointerstitial nephritis).
Acute Kidney Injury
Tubulointerstitial Nephritis
3. ACUTE KIDNEY INJURY (AKI) (ACUTE
TUBULAR NECROSIS, ATN)
ATN is a clinicopathologic entity
characterized clinically by
Acute reduction of renal function and
often, but not invariably, morphologic
evidence of tubular injury.
4. AKI / ATI / ATN
• It is the most common cause of
acute renal failure,
which signifies rapid reduction of
renal function and urine flow, falling
within 24 hours to less than 400 mL per
day.
5. Causes of AKI
1. Ischemia due to decreased or interrupted
blood flow,
2. Direct toxic injury to the tubules
3. Acute tubulointerstitial nephritis
4. Urinary obstruction
6. ISCHEMIA
• Examples:
• diffuse involvement of the intrarenal blood vessels
such as in microscopic polyangiitis, malignant
hypertension, microangiopathies
• systemic conditions associated with thrombosis
(e.g., hemolytic uremic syndrome [HUS],
thrombotic thrombocytopenic pupura [TTP],
• disseminated intravascular coagulation [DIC]),
• decreased effective circulating blood volume
7. • Direct toxic injury to the tubules (e.g., by
drugs, radiocontrast dyes, myoglobin,
hemoglobin, radiation)
• • Acute tubulointerstitial nephritis, most
commonly occurring as a hypersensitivity
reaction to drugs
• • Urinary obstruction by tumors, prostatic
hypertrophy, or blood clots (so-called
postrenal acute renal failure))
10. Pathogenesis
• The critical events in both ischemic and
nephrotoxic AKI are believed to be
(1) Tubular injury and
(2)Disturbances in blood flow
11. Pathogenesis-Tubule cell injury
• Tubular epithelial cells are
particularly
•Sensitive to ischemia
and are also
•Vulnerable to toxins.
12. Pathogenesis Tubular Injury
Ischemia causes numerous structural and
functional alterations in epithelial cells.
The structural changes include those of
reversible injury (such as cellular swelling,
loss of brush border and polarity, blebbing,
and cell detachment) and
those associated with lethal injury (necrosis
and apoptosis).
TubularInjury
13. Pathogenesis: Biochemical changes
• Depletion of ATP;
• Accumulation of intracellular calcium;
• Activation of proteases (e.g., calpain).
Tubular Injury
14. Pathogenesis: Biochemical changes cause:
• Cytoskeletal disruption;
• Activation of phospholipases, which damage
membranes;
• Generation of reactive oxygen species; and
• Activation of caspases,
• which induce apoptotic cell death.
Tubular Injury
15. Cell polarity refers to spatial differences in the shape, structure, and function of cells.
• One early reversible result of ischemia is loss of
cell polarity due to redistribution of membrane
proteins (e.g., the enzyme Na+
, K+
-ATPase) from the
basolateral to the luminal surface of the tubular
cells, resulting in abnormal ion transport
across the cells, and
• increased sodium delivery to distal tubules.
• The latter incites vasoconstriction via
tubuloglomerular feedback.
Pathogenesis
Tubular Injury
16. Pathogenesis- Cytokines & Adhesion molecules
• In addition, ischemic tubular cells express
cytokines (such as monocyte
chemoattractant protein 1) and adhesion
molecules (such as intercellular adhesion
molecule 1), thus recruiting leukocytes
that appear to participate in the subsequent
injury.
Tubular Injury
17. Pathogenesis
• In time, injured cells detach from the
basement membranes and cause luminal
obstruction, increased intratubular
pressure, and decreased GFR.
Tubular Injury
18. Pathogenesis
• In addition, fluid from the damaged tubules
leaks into the interstitium, resulting in
interstitial edema, increased interstitial
pressure, and further damage to the
tubule. All these effects contribute to the
decreased GFR.
Tubular
Injury
19. Pathogenesis Disturbances in blood flow
Ischemic renal injury is also characterized by
hemodynamic alterations
that cause reduced GFR.
•
20. Pathogenesis Disturbances in blood flow
The major one is
intrarenal vasoconstriction, which
results in both
• reduced glomerular blood flow and
• reduced oxygen delivery to the functionally important
tubules in the outer medulla
(thick ascending limb and straight segment of the
proximal tubule).
Hemodynamic alterations
21. Several vasoconstrictor pathways
have been implicated, including:
• The renin-angiotensin system, stimulated by
increased distal sodium delivery (via
tubuloglomerular feedback), and sublethal
endothelial injury, leading to increased release of
the vasoconstrictor endothelin and decreased
production of the vasodilators nitric oxide and
prostacyclin (prostaglandin I2).
Pathogenesis- Disturbances in blood flow- vasoconstriction
22. Pathogenesis
• There is also some evidence of
• a directeffect of ischemia or toxins on
the glomerulus,
causing a reduced glomerular ultrafiltration
coefficient,
possibly due to mesangial contraction.
23. Pathogenesis
• The patchiness of tubular necrosis and
maintenance of the integrity of the basement
membrane along many segments allow ready
repair of the necrotic foci and recovery of
function if the precipitating cause is
removed.
• This repair is dependent on the capacity of
reversibly injured epithelial cells to
proliferate and differentiate.
24. Re-epithelialization is mediated by a variety of
growth factors and cytokines:
1. Autocrine stimulation:
Produced locally by the tubular cells
themselves
2. Paracrine stimulation:
By inflammatory cells in the vicinity of necrotic
foci.
Pathogenesis
25. Pathogenesis
Re-epitheliazation by growth factors:
1. Epidermal growth factor,
2. TGF-α,
3. Insulin-like growth factor type 1, and
4. Hepatocyte growth factor
are particularly important in renal tubular
repair.
26. Structural & Functional alteration in
Epithelial cells:Biochemical Changes
From basement membrane
Injured cells
Luminal
Disturbances in blood flow
Hemodynamic alterations
Vasoconstrictor pathways
↓ATP
↑Ca
Act.of caspases
Reepithilization by cytokines & growth factors
Cytokines + Adhesion
Molecules=Leukocytes=Injury
In addition, fluid from the damaged tubules
leaks into the interstitium, resulting in
interstitial edema, increased interstitial
pressure, and further damage to the
tubule. All these effects contribute to the
decreased GFR.
27. Morphology Ischemic AKI
• focal tubular epithelial necrosis
at multiple points along the nephron, with large skip areas in
between, often accompanied by
• rupture of basement membranes
(tubulorrhexis) and
• occlusion of tubular lumens by
casts.
28. Morphology of Ischemic AKI
• The straight portion of the proximal tubule
and the ascending thick limb in the renal
medulla are especially vulnerable,
but focal lesions may also occur in the distal
tubule, often in conjunction with casts.
29. Morphology Ischemic AKI
•Eosinophilic hyaline casts,
as well as pigmented granular casts,
are common, particularly in
distal tubules and
collecting ducts.
30. Morphology of Ischemic AKI
• These casts consist principally of
Tamm-Horsfall protein
(a urinary glycoprotein normally secreted by
the cells of ascending thick limb and distal
tubules) in conjunction with other plasma
proteins.
31. Morphology of Ischemic AKI
• Other findings in ischemic AKI are
interstitial edemaand
accumulations of leukocytes within
dilated vasa recta.
32. There is also evidence of epithelial
regeneration:
Flattened epithelial cells with
hyperchromatic nuclei and
mitotic figures are often present.
In the course of time this regeneration
repopulates the tubules so that, no residual
evidence of damage is seen.
33. Toxic AKI
• Toxic AKI is manifested by
acute tubular injury,
most obvious in the proximal convoluted
tubules.
34. Toxic AKI
• On histologic examination
• the tubular necrosis
may be entirely nonspecific, but it is
somewhat distinctive in poisoning with
certain agents.
35. Toxic AKI with Mercuric chloride
• Severely injured cells may contain
large acidophilic inclusions.
Later, these cells become totally necrotic, are
desquamated into the lumen, and may
undergo calcification.
36. Toxic AKI Carbon tetrachloride poisoning
• is characterized by
• the accumulation of neutral lipids in injured
cells; followed by necrosis.
37. Toxic AKI Ethylene glycol
• produces marked ballooning and
• hydropic or vacuolar degeneration
of proximal convoluted tubules.
• Calcium oxalate crystals are often found
in the tubular lumens in such poisoning.
38.
39. Clinical Course
The clinical course of AKI is highly variable, but
the classic case may be divided into
1.initiation,
2. maintenance, and
3.recovery
stages.
40. The initiation phase
Lasting for about 36 hours, is dominated
by the inciting medical, surgical, or obstetric
event in the ischemic form of AKI.
41. The Initiation Phase
• The only indication of renal involvement is a
slight decline in urine output with a rise in
BUN.
• At this point, oliguria could be explained
on the basis of a transient decrease in
blood flow and declining GFR.
42. The maintenance phase
• is characterized by
sustained decreases in urine output to
between 40 and 400 mL/day (oliguria),
salt and water overload,
rising BUN concentrations,
hyperkalemia,
metabolic acidosis, and
other manifestations of uremia.
43. The recovery phase
• a steady increase in urine volume that may
reach up to 3 L/day.
• The tubules are still damaged, so large
amounts of water, sodium, and potassium
are lost in the flood of urine.
44. The recovery phase
•Hypokalemia, rather than
hyperkalemia, becomes a clinical problem.
There is a peculiar increased vulnerability to
infectionat this stage.
45. The recovery phase
• Eventually, renal tubular function is restored
and concentrating ability improves. At the
same time, BUN and creatinine levels begin
to return to normal. Subtle tubular functional
impairment may persist for months, but
most patients who reach this phase
eventually recover completely.
46. Nonoliguric AKI
• Up to 50% of patients with AKI do not have
oliguria and instead often have increased
urine volumes.
• This so-called nonoliguric AKI
occurs particularly often with nephrotoxins,
and it generally tends to follow a more
benign clinical course.
47. Prognosis
• With current supportive care, 95%
Conversely, in shock related to sepsis,
extensive burns, or other causes of multi-
organ failure, the mortality rate can rise to
more than 50%.